コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ably quantify AAR and final IS in reperfused acute myocardial infarction.
2 gency department with symptoms suggestive of acute myocardial infarction.
3 mproving heart function after injury such as acute myocardial infarction.
4 eafter has been shown to accurately rule out acute myocardial infarction.
5 al mechanisms, and outcomes in patients with acute myocardial infarction.
6 ictive value (NPV) for the identification of acute myocardial infarction.
7 omen are at highest risk after discharge for acute myocardial infarction.
8 stratification in contemporary patients with acute myocardial infarction.
9 ing 30-day risk-standardized mortality after acute myocardial infarction.
10 the predictive power of ETA in survivors of acute myocardial infarction.
11 flow grade 3 patency in 15% of patients with acute myocardial infarction.
12 onary atherosclerotic plaques commonly cause acute myocardial infarction.
13 diogenic shock during hospitalization for an acute myocardial infarction.
14 e for discharge, with a high sensitivity for acute myocardial infarction.
15 dynamics of CSL112 in patients with a recent acute myocardial infarction.
16 ology, treatment, and outcomes of women with acute myocardial infarction.
17 tal mortality for contemporary patients with acute myocardial infarction.
18 diogenic shock in patients hospitalized with acute myocardial infarction.
19 h proved little better than streptokinase in acute myocardial infarction.
20 e recovery in multiple health outcomes after acute myocardial infarction.
21 ovements were observed for heart failure and acute myocardial infarction.
22 s compared with congestive heart failure and acute myocardial infarction.
23 ients presenting with symptoms suggestive of acute myocardial infarction.
24 onary artery bypass grafting, and reperfused acute myocardial infarction.
25 symptoms they actually experienced during an acute myocardial infarction.
26 diac arrest patients and awake patients with acute myocardial infarction.
27 subset of Medicare patients presenting with acute myocardial infarction.
28 or hospital admission of those who died from acute myocardial infarction.
29 ality indicators (QIs) for the management of acute myocardial infarction.
30 ntribute to reducing the mortality burden of acute myocardial infarction.
31 ould mitigate the risk of plaque rupture and acute myocardial infarction.
32 about deaths and hospital admissions due to acute myocardial infarction.
33 cular events, particularly heart failure and acute myocardial infarction.
34 gastrointestinal bleeding, 1.28 (1.14-1.44); acute myocardial infarction, 0.92 (0.78-1.08); and death
35 ause mortality, 1.82 (95% CI, 1.15-2.88) for acute myocardial infarction, 1.97 (95% CI, 1.04-3.73) fo
36 se mortality, 12.34 (95% CI, 7.91-19.48) for acute myocardial infarction, 15.09 (95% CI, 9.87-23.09)
37 here were sustained decreases in PAC use for acute myocardial infarction (20.0 PACs placed per 1000 a
38 additional criteria required for spontaneous acute myocardial infarction (280/397, 71%) versus those
40 32% versus 19%; hypotension, 14% versus 4%; acute myocardial infarction, 4% versus 2%; cardiac arres
41 1995 to 2015, including 14 423 patients with acute myocardial infarction (59% STEMI) admitted to card
43 patient mortality among hospitalizations for acute myocardial infarction (adjusted odds ratio [OR]: 0
44 in 28 days of being in hospital follow a non-acute myocardial infarction admission as follow an acute
49 s investigating the effect of MSC therapy in acute myocardial infarction (AMI) and chronic ischemic c
50 s investigating the effect of MSC therapy in acute myocardial infarction (AMI) and chronic ischemic c
51 s well as in plasma samples of patients with acute myocardial infarction (AMI) and in control plasma
52 ne the association between HIV infection and acute myocardial infarction (AMI) and stroke outcomes, w
53 isk-standardized mortality rates (RSMRs) for acute myocardial infarction (AMI) are calculated for Med
54 tance: Most younger adults who experience an acute myocardial infarction (AMI) are sexually active be
56 Despite advances in treatment, mortality in acute myocardial infarction (AMI) complicated by cardiog
59 ity cardiac troponin-T (hs-cTnT) in a 1-hour acute myocardial infarction (AMI) exclusion algorithm.
60 695 Medicare beneficiaries diagnosed with an acute myocardial infarction (AMI) for which we had compl
61 emergency department patients with possible acute myocardial infarction (AMI) has been shown to effe
62 nts on dialysis revealed that mortality from acute myocardial infarction (AMI) has decreased, whereas
64 of bone marrow (BM) mononuclear cells after acute myocardial infarction (AMI) has led to limited imp
66 st studies of sex and race differences after acute myocardial infarction (AMI) have not taken into ac
67 e-based medication therapy in patients after acute myocardial infarction (AMI) improves long-term pro
68 s are prospectively associated with incident acute myocardial infarction (AMI) in a large cohort of a
69 , the identification of the first (incident) acute myocardial infarction (AMI) in an individual is ba
70 ardiology guidelines to rule-in and rule-out acute myocardial infarction (AMI) in the emergency depar
71 the incidence and mortality associated with acute myocardial infarction (AMI) in the United States h
75 n about the impact of hospitalization for an acute myocardial infarction (AMI) on subsequent adherenc
80 t patients are at higher risk of death after acute myocardial infarction (AMI) than normal weight pat
81 ficiency virus (HIV+) have a greater risk of acute myocardial infarction (AMI) than uninfected indivi
82 telet therapy (DAPT) is recommended after an acute myocardial infarction (AMI) to reduce ischemic eve
83 (HDs) and 14 plasma samples of patients with acute myocardial infarction (AMI) was carried out with s
85 an quantify the area-at-risk (AAR) following acute myocardial infarction (AMI), and has been used to
87 rehabilitation (CR) improves survival after acute myocardial infarction (AMI), and referral to CR ha
88 t in 30-day RSRRs after hospitalizations for acute myocardial infarction (AMI), congestive heart fail
89 t in 30-day RSRRs after hospitalizations for acute myocardial infarction (AMI), congestive heart fail
90 alizes hospitals for excess readmissions for acute myocardial infarction (AMI), heart failure (HF), a
91 13 in VA and non-VA acute care hospitals for acute myocardial infarction (AMI), heart failure (HF), o
92 xperience high rates of adverse events after acute myocardial infarction (AMI), including death and r
94 e), defined as in-hospital, all-cause death, acute myocardial infarction (AMI), or acute ischemic str
95 and increasing attention to young women with acute myocardial infarction (AMI), who represent an extr
108 e death are used to diagnose a heart attack (acute myocardial infarction, AMI), there is no biomarker
109 mortality and strokes, a lower incidence of acute myocardial infarctions (AMIs) and SVTs, and an inc
110 he PROMIS cohort included 9015 patients with acute myocardial infarction and 8629 matched controls.
111 suggests that it can reduce infarct size in acute myocardial infarction and acute ischemic stroke.
112 ed heart failure, pulmonary hypertension, or acute myocardial infarction and after major cardiac surg
114 lization files, we identified discharges for acute myocardial infarction and cardiac arrest January 2
116 c cardioplegic arrest is only a surrogate of acute myocardial infarction and confounded by the choice
118 tor for sudden cardiac death in survivors of acute myocardial infarction and for those with congestiv
119 tional VA administrative data, we identified acute myocardial infarction and heart failure discharges
120 l risk factors were at target, with risk for acute myocardial infarction and heart failure hospitaliz
124 left ventricular (LV) dysfunction both post-acute myocardial infarction and in ischemic cardiomyopat
125 ies were larger, treating more patients with acute myocardial infarction and performing more PCIs tha
126 ed 706 patients who had multivessel disease, acute myocardial infarction, and cardiogenic shock to on
127 nplanned rehospitalizations are common after acute myocardial infarction, and close to one third were
128 125 231 hospitalizations for heart failure, acute myocardial infarction, and pneumonia, respectively
130 s recorded in 21 patients were indicative of acute myocardial infarction, and there were no differenc
131 itals in the early survival of patients with acute myocardial infarction are associated with differen
132 -day risk-standardized mortality rates after acute myocardial infarction are commonly used to evaluat
134 magnetic resonance imaging in patients after acute myocardial infarction as a biosignal for left vent
135 950 deaths were recorded as being caused by acute myocardial infarction as the underlying cause of d
136 l infarction diagnosis but went on to die of acute myocardial infarction as the underlying cause of d
137 lity rates for heart failure, pneumonia, and acute myocardial infarction, as well as readmission pena
138 s of central Massachusetts hospitalized with acute myocardial infarction at all 11 medical centers in
140 in-hospital outcomes of patients treated for acute myocardial infarction before and after a hospital
141 care beneficiaries who were hospitalized for acute myocardial infarction between 1994 and 1996 and wh
142 grafting for cardiogenic shock complicating acute myocardial infarction between January 2000 and Jun
143 ived cells (CDCs) confer cardioprotection in acute myocardial infarction by distinctive macrophage (M
144 ily cardiac history, and were informed about acute myocardial infarction by relatives expected fewer
145 tween the two, and the overall management of acute myocardial infarction can be reviewed for simplici
146 subo syndrome (TTS) generally presents as an acute myocardial infarction characterized by severe left
148 nary artery bypass grafting in patients with acute myocardial infarction complicated by cardiogenic s
149 and clinical outcomes in 7195 subjects with acute myocardial infarction complicated by reduced left
150 ly administered off-the-shelf early after an acute myocardial infarction, comply with stringent crite
151 r older admitted for five medical diagnoses (acute myocardial infarction, congestive heart failure, s
152 ion is available on how primary and comorbid acute myocardial infarction contribute to the mortality
153 of (18)F-FDG uptake in the myocardium after acute myocardial infarction correlated inversely with fu
156 x groups) and case-fatality rate for primary acute myocardial infarction diagnosed during the first p
157 counter or during subsequent encounters, and acute myocardial infarction diagnosed only as a comorbid
158 s of admission in people who did not have an acute myocardial infarction diagnosis but went on to die
159 rtality among patients who were admitted for acute myocardial infarction (difference-in-differences e
162 entify all primary and comorbid diagnoses of acute myocardial infarction during hospital stay and the
164 of-concept of efficacy of IL-4 treatment for acute myocardial infarction, encouraging its further dev
166 ivity Troponin-T Assay for Rapid Rule-Out of Acute Myocardial Infarction) evaluated high-sensitivity
168 Blood obtained from patients diagnosed with acute myocardial infarction exhibited significantly high
169 emiological trends, and modern management of acute myocardial infarction, focusing on the recent adva
171 Patients with cardiogenic shock complicating acute myocardial infarction from 2002 to 2011 were ident
173 admitted to high-performing hospitals after acute myocardial infarction had longer life expectancies
175 emic conditioning protocols to patients with acute myocardial infarction has been fairly successful,
176 decades, the holy grail in the treatment of acute myocardial infarction has been the mitigation of l
177 r the past 20 years, 6-month mortality after acute myocardial infarction has decreased considerably f
179 CAREMI (Cardiac Stem Cells in Patients With Acute Myocardial Infarction) has been designed as a doub
181 us studies examining early readmission after acute myocardial infarction have focused exclusively on
182 rd rate ratio for women versus men, 1.10 for acute myocardial infarction; hazard rate ratio, 1.04 for
184 tensive patients, and exclusive of trials in acute myocardial infarction, heart failure, acute stroke
185 cTnI) levels are associated with the risk of acute myocardial infarction, heart failure, and cardiova
186 ons between cTnI levels and the incidence of acute myocardial infarction, heart failure, and cardiova
187 ly but started reporting mortality rates for acute myocardial infarction, heart failure, and pneumoni
188 roups and key clinical conditions, including acute myocardial infarction, heart failure, and respirat
189 tients who were admitted to the hospital for acute myocardial infarction, heart failure, or pneumonia
190 ere examined from 4 clinical areas (surgery, acute myocardial infarction, heart failure, pneumonia),
191 utcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and European
192 utcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) clinical tria
194 nously injected nanoparticles at the site of acute myocardial infarction in a rat model is described.
196 haracteristics, treatments, and outcomes for acute myocardial infarction in France between 1995 and 2
197 t can be used to predict the risk of a fatal acute myocardial infarction in such patients, which can
198 Seven hundred twenty-four patients with acute myocardial infarction in the coronary care program
200 %) of 446 744 admissions with a diagnosis of acute myocardial infarction, in the second or later phys
204 hospital cardiac arrest is common because of acute myocardial infarction, it is unknown whether early
205 cardiac stem cell in 55 patients with large acute myocardial infarction, left ventricular dysfunctio
207 oblasts with injury to mediate healing after acute myocardial infarction (MI) and to mediate long-sta
209 t therapy may be different for patients with acute myocardial infarction (MI) compared with more stab
210 spital cardiac arrest (OHCA) associated with acute myocardial infarction (MI) confers high in-hospita
211 ital treatment and outcomes of patients with acute myocardial infarction (MI) have been described, bu
212 ls of bone marrow cell-based therapies after acute myocardial infarction (MI) have produced mostly ne
213 Recent studies reported an increased risk of acute myocardial infarction (MI) in PPI users vs non-use
214 e receptor activation with fingolimod during acute myocardial infarction (MI) inhibits apoptosis, lea
217 233 US hospitals within 1 year of the index acute myocardial infarction (MI) of 12365 patients enrol
219 admission rates for patients discharged with acute myocardial infarction (MI), heart failure (HF), or
224 ay be contributing to young women's elevated acute myocardial infarction mortality relative to men.
226 primary outcome was a composite of nonfatal acute myocardial infarction, nonfatal stroke, or cardiov
227 so calculated what proportion of deaths from acute myocardial infarction occurred in people who had b
228 The primary outcome was fatal or nonfatal acute myocardial infarction occurring within 30 days of
229 Well into the 21st century, we still triage acute myocardial infarction on the basis of the presence
230 alyzed Medicare data on hospitalizations for acute myocardial infarction or cardiac arrest among Medi
231 admitted to marathon-affected hospitals with acute myocardial infarction or cardiac arrest on maratho
233 ity without significantly increased risk for acute myocardial infarction or hospitalization for gastr
235 n myocardial strain imaging in patients with acute myocardial infarction or stable ischemic heart dis
236 are characteristics of patients suffering an acute myocardial infarction or undergoing cardiovascular
237 was the composite of incident heart failure, acute myocardial infarction, or cardiovascular death.
238 ticipants were diagnosed with heart failure, acute myocardial infarction, or cardiovascular death.
240 ncipal discharge diagnosis of heart failure, acute myocardial infarction, or pneumonia and estimated
241 eneficiaries hospitalized for heart failure, acute myocardial infarction, or pneumonia, reductions in
242 Patients with diagnosis of brain injury, acute myocardial infarction, or status postcardiac surge
244 arch Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status) is
245 arch Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status).
246 a rigorously imaging-based selected group of acute myocardial infarction patients, with detailed safe
248 Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction [PRAGUE-18]; NCT02808767).
249 Ventricle and Congestive Heart Failure After Acute Myocardial Infarction [PRESERVATION I]; NCT0122656
250 ncluding heart failure (r = 0.39; P < 0.01), acute myocardial infarction (r = 0.30; P < 0.01), pneumo
253 tient or observation rehospitalization after acute myocardial infarction represents a significant eve
255 I, 1.46 to 1.72) and a 40% increased risk of acute myocardial infarction (RR 1.40; 95% CI, 1.23 to 1.
256 hter's syndrome, two sepsis, and one each of acute myocardial infarction, septic shock, encephalopath
257 c natural killer cell depletion 24 hours pre-acute myocardial infarction significantly improved infar
258 uclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological in
259 Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction) study did not find any sign
260 of uPA was administered to 101 patients with acute myocardial infarction; superior infarct artery pat
264 During Percutaneous Coronary Intervention in Acute Myocardial Infarction], TASTE [Thrombus Aspiration
265 rction contribute to the mortality burden of acute myocardial infarction, the share of these deaths t
266 64 for mortality among patients admitted for acute myocardial infarction to 2615 for mortality among
269 cy and safety of prasugrel and ticagrelor in acute myocardial infarction treated with primary or imme
270 utcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial, 3,602 patients under
271 In the CYCLE (CYCLosporinE A in Reperfused Acute Myocardial Infarction) trial, a single intravenous
272 utcomes with Revascularization and Stents in Acute Myocardial Infarction) trial, all ischemic and ble
273 of METOprolol of CARDioproteCtioN during an acute myocardial InfarCtion) trial, which randomized ant
274 aim of this study was to investigate whether acute myocardial infarction triggers an inflammatory T-c
275 ing infarct size in patients with reperfused acute myocardial infarction; unfortunately, for these dr
276 udicated diagnosis of 30-day MACE defined as acute myocardial infarction, unstable angina, cardiogeni
277 Four strategies for very early rule-out of acute myocardial infarction using high-sensitivity cardi
278 ponin I (cTnI), a biomarker for diagnosis of acute myocardial infarction, using silicon nanowire fiel
279 emia, coagulopathy, obesity, major bleeding, acute myocardial infarction, vascular complications, and
280 additional criteria required for spontaneous acute myocardial infarction versus those patients who do
282 s the case-fatality rate of patients in whom acute myocardial infarction was a primary diagnosis.
284 hin the 28 days preceding death, and whether acute myocardial infarction was one of the recorded diag
287 olled trial, participants presenting with an acute myocardial infarction were randomly assigned 1:1 t
288 s was performed when spontaneously occurring acute myocardial infarctions were diagnosed by imaging.
289 characteristics in patients who have had an acute myocardial infarction while receiving current guid
290 ot been clearly established in patients with acute myocardial infarction who are undergoing percutane
291 ne oxygen therapy in patients with suspected acute myocardial infarction who do not have hypoxemia at
292 study sample included 119,735 patients with acute myocardial infarction who were admitted to 1824 ho
293 ents (57 years +/- 12; 78% men) with a first acute myocardial infarction, who were prospectively enro
295 had multivessel coronary artery disease and acute myocardial infarction with cardiogenic shock, the
297 had worse recovery than men at 1 month after acute myocardial infarction, with mean differences in im
298 s been investigated in patients suffering an acute myocardial infarction, with the final aim of salva
300 r Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure; NCT02
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。